University of Minnesota Cancer Center Achieves ‘Comprehensive’ Status
The University of Minnesota Cancer Center has been designated a "comprehensive cancer center" by the National Cancer Institute. To quality for the title "comprehensive," a center must conduct basic and clinical research, as well as prevention, control, and population studies; exhibit a strong body of interactive research bridging these key areas; and have outreach, education, and information programs in place. Only 35 of the 58 NCI-designated cancer centers meet the requirements for the "comprehensive" designation.
The University of Minnesota Cancer Center has been designated a "comprehensive cancer center" by the National Cancer Institute. To quality for the title "comprehensive," a center must conduct basic and clinical research, as well as prevention, control, and population studies; exhibit a strong body of interactive research bridging these key areas; and have outreach, education, and information programs in place. Only 35 of the 58 NCI-designated cancer centers meet the requirements for the "comprehensive" designation.
"Were extremely pleased that the National Cancer Institute and our national peers have recognized the breadth of our cancer research program as well as our efforts to serve the community," said John H. Kersey, MD, director of the University of Minnesota Cancer Center. The University of Minnesota Cancer Center is the only NCI-designated comprehensive cancer center in the state of Minnesota
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F7d7dfad7849391f4be3ebd2cf39c24f5369cfcd1-1200x1176.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).")
